TGTX End Period Cash Flow from 2010 to 2025

TGTX Stock  USD 29.55  0.41  1.41%   
TG Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 61 M in 2025. During the period from 2010 to 2025, TG Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.16 and arithmetic mean of  101,568,798. View All Fundamentals
 
End Period Cash Flow  
First Reported
1996-09-30
Previous Quarter
82.9 M
Current Value
197.1 M
Quarterly Volatility
95.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 510.8 K, Interest Expense of 15.2 M or Total Revenue of 282.1 M, as well as many indicators such as Price To Sales Ratio of 8.87, Dividend Yield of 4.0E-4 or PTB Ratio of 14.28. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of TG Therapeutics over the last few years. It is TG Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

TGTX End Period Cash Flow Regression Statistics

Arithmetic Mean101,568,798
Geometric Mean51,957,719
Coefficient Of Variation137.25
Mean Deviation83,254,851
Median56,717,847
Standard Deviation139,406,388
Sample Variance19434.1T
Range552.5M
R-Value0.39
Mean Square Error17584.3T
R-Squared0.16
Significance0.13
Slope11,546,777
Total Sum of Squares291512.1T

TGTX End Period Cash Flow History

202561 M
202494.2 M
202392.9 M
2022103.6 M
2021300.2 M
2020554.7 M
2019113.9 M

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow94.2 M61 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.